This is a working overview of regulatory status, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-09. Anything still debated is marked as such rather than presented as settled.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
In June 1964, 144 test persons survived for six days in a civilian nuclear bunker. The bunker in Dortmund had been built during the Second World War and had been converted at great expense in the early 1960s into a nuclear-weapon-proof building. However, it would be impossible to build a bunker for millions of German citizens. The Swiss Army built about 7800 nuclear fallout shelters in 1964. In the United States in particular, but also Europe, citizens built private fallout shelters in their front yards on their initiative. This construction was largely kept secret because the owners feared that third parties might take possession of the bunker in the event of a crisis.
== Reference terminology == The terminology of isotopic reference materials is not applied consistently across subfields of isotope geochemistry or even between individual laboratories. The terminology defined below comes from Gröening et al. (1999) and Gröening (2004). Reference materials are the basis for accuracy across many different types of measurement, not only the mass spectrometry, and there is a large body of literature concerned with the certification and testing of reference materials.
Åland Islands Peace Institute Demos Helsinki European Centre of Excellence for Countering Hybrid Threats (Hybrid CoE) Crisis Management Initiative (CMI) Research Institute of the Finnish Economy (Etla) Finnish Institute of International Affairs In addition to specific independent think tanks, the largest political parties have their own think tank organizations. This is mainly due to support granted by state for such activity. The corporate world has focused their efforts to central representative organization Confederation of Finnish Industries, which acts as think tank in addition to negotiating salaries with workers unions. Furthermore, there is the Finnish Business and Policy Forum (Elinkeinoelämän valtuuskunta, EVA). Agricultural and regional interests, associated with The Central Union of Agricultural Producers and Forest Owners (Maa- ja metsätaloustuottajain Keskusliitto, MTK) and the Centre Party, are researched by Pellervo Economic Research (Pellervon taloustutkimus, PTT). The Central Organisation of Finnish Trade Unions (Suomen Ammattiliittojen Keskusjärjestö, SAK) and the Social Democratic Party are associated with the Labour Institute for Economic Research (Palkansaajien tutkimuslaitos, PT). Each of these organizations often release forecasts concerning the national economy.
Sources: en.wikipedia.org
Houseplants together with the medium in which they are grown can reduce components of indoor air pollution, particularly volatile organic compounds (VOC) such as benzene, toluene, and xylene. Plants remove CO2 and release oxygen and water, although the quantitative impact for house plants is small. The interest in using potted plants for removing VOCs was sparked by a 1989 NASA study conducted in sealed chambers designed to replicate the environment on space stations. However, these results suffered from poor replication and are not applicable to typical buildings, where outdoor-to-indoor air exchange already removes VOCs at a rate that could only be matched by the placement of 10–1000 plants/m2 of a building's floor space. Plants also appear to reduce airborne microbes and molds, and to increase humidity. However, the increased humidity can itself lead to increased levels of mold and even VOCs. Since extremely high humidity is associated with increased mold growth, allergic responses, and respiratory responses, the presence of additional moisture from houseplants may not be desirable in all indoor settings if watering is done inappropriately.
Even though it did not show any protein-protein interactions, it could be used to detect inhibitor-induced protein conformational changes in the cell membranes on top of determining oligomeric structures.
Centers for Disease Control: Obesity Data and Statistics American Obesity Treatment Association: Obesity Education and Statistics Archived February 28, 2021, at the Wayback Machine Contributors to Obesity | Tableau Public Archived January 3, 2015, at the Wayback Machine (infographic for the United States)
Radionuclides are produced in stellar nucleosynthesis and supernova explosions along with stable nuclides. Most decay quickly, but some can be observed astronomically and can play a part in understanding astrophysical processes. Primordial radionuclides, such as uranium and thorium, still exist because their half-lives are so long (>100 million years) that the Earth's initial content has not yet completely decayed. Some radionuclides have half-lives so long (many times the age of the universe) that decay has only recently been detected, and for most practical purposes they can be considered stable, most notably bismuth-209: detection of this decay meant that bismuth was no longer considered stable. It is possible that decay may be observed in other nuclides now considered stable, adding to the list of primordial radionuclides. Secondary radionuclides are radiogenic isotopes derived from the decay of primordial radionuclides. They have shorter half-lives than primordial radionuclides. They arise in the decay chain of the primordial isotopes thorium-232, uranium-238, and uranium-235 - such as the natural isotopes of polonium and radium - some are also produced by natural fission and other nucleogenic processes. Cosmogenic isotopes, such as carbon-14, are present because they are continually being formed on Earth, typically in the atmosphere, due to the action of cosmic rays. Many of these radionuclides exist only in trace amounts in nature, including all cosmogenic nuclides.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.